DMAC Stock Summary and Trading Ideas (Diamedica Therapeutics | NASDAQ:DMAC)

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.

Diamedica Therapeutics trades on the NASDAQ stock market under the symbol DMAC.

As of January 17, 2025, DMAC stock price climbed to $5.71 with 248,479 million shares trading.

DMAC has a market cap of $244.06 million. This is considered a Small Cap stock.

In the last 3 years, DMAC traded as high as $6.41 and as low as $1.12.

The top ETF exchange traded funds that DMAC belongs to (by Net Assets): VTI, VXF, IWC, AVSC.

DMAC has outperformed the market in the last year with a price return of +106.9% while the SPY ETF gained +28.0%. DMAC has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +33.1% and +2.7%, respectively, while the SPY returned +3.0% and +1.0%, respectively.

DMAC support price is $5.36 and resistance is $5.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DMAC shares will trade within this expected range on the day.